Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.

Various melatonin supplementations have been developed to improve health outcomes in various clinical conditions. Thus, we sought to evaluate and summarize the effect of melatonin treatments in clinical settings for health outcomes. We searched PubMed/Medline, Embase, and Cochrane Library from incep...

Descripción completa

Detalles Bibliográficos
Autores: Lim S, Park S, Koyanagi A, Yang JW, Jacob L, Yon DK, Lee SW, Kim MS, Il Shin J, Smith L
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2022
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p20521
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20521
Access Level:acceso abierto
Palabra clave:Alprazolam (PubChem CID:2118)
Clinical outcome
Clozapine (PubChem CID:135398737)
Inositol (PubChem CID:892)
Melatonin
Melatonin (PubChem CID:896)
Midazolam (PubChem CID:4192)
Olanzapine (PubChem CID:135398745)
Oxazepam (PubChem CID:4616)
Quetiapine (PubChem CID:5002)
Randomized controlled trial
Risperidone (PubChem CID:5073)
Umbrella review
id ES_c9fa437fa2491bb54c4253b74b290eae
oai_identifier_str oai:fsjd.fundanetsuite.com:p20521
network_acronym_str ES
network_name_str España
repository_id_str
spelling Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.Lim SPark SKoyanagi AYang JWJacob LYon DKLee SWKim MSIl Shin JSmith LAlprazolam (PubChem CID:2118)Clinical outcomeClozapine (PubChem CID:135398737)Inositol (PubChem CID:892)MelatoninMelatonin (PubChem CID:896)Midazolam (PubChem CID:4192)Olanzapine (PubChem CID:135398745)Oxazepam (PubChem CID:4616)Quetiapine (PubChem CID:5002)Randomized controlled trialRisperidone (PubChem CID:5073)Umbrella reviewVarious melatonin supplementations have been developed to improve health outcomes in various clinical conditions. Thus, we sought to evaluate and summarize the effect of melatonin treatments in clinical settings for health outcomes. We searched PubMed/Medline, Embase, and Cochrane Library from inception to 4 February 2021. We included meta-analyses of randomized controlled trials investigating the melatonin intervention for any health outcome. Based on the different effect sizes of each meta-analysis, we calculated random models' standardized mean differences or risk ratios. We observed robust evidence supported by statistical significance with non-considerable heterogeneity between studies for sleep-related problems, cancer, surgical patients, and pregnant women. Patients with sleep disorder, sleep onset latency (SMD 0.33, 95% CI: 0.10 - 0.56, P < 0.01) were significantly improved whereas no clear evidence was shown with sleep efficiency (1.10, 95% CI: -0.26 to 2.45). The first analgesic requirement time (SMD 5.81, 95% CI: 2.57-9.05, P < 0.001) of surgical patients was distinctly improved. Female patients under artificial reproductive technologies had significant increase in the top-quality embryos (SMD 0.53, 95% CI: 0.27 - 0.79, P < 0.001), but no statistically clear evidence was found in the live birth rate (SMD 1.20, 95% CI: 0.83 - 1.72). Survival at one year (RR 1.90, 95% CI: 1.28 - 2.83, P < 0.005) significantly increased with cancer patients. Research on melatonin interventions to treat clinical symptoms and sleep problems among diverse health conditions was identified and provided considerable evidence. Future well-designed randomized clinical trials of high quality and subgroup quantitative analyses are essential.ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD2022info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20521PHARMACOLOGICAL RESEARCHISSN: 10436618ISSNe: 10961186reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p205212026-05-27T12:37:41Z
dc.title.none.fl_str_mv Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
title Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
spellingShingle Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
Lim S
Alprazolam (PubChem CID:2118)
Clinical outcome
Clozapine (PubChem CID:135398737)
Inositol (PubChem CID:892)
Melatonin
Melatonin (PubChem CID:896)
Midazolam (PubChem CID:4192)
Olanzapine (PubChem CID:135398745)
Oxazepam (PubChem CID:4616)
Quetiapine (PubChem CID:5002)
Randomized controlled trial
Risperidone (PubChem CID:5073)
Umbrella review
title_short Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
title_full Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
title_fullStr Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
title_full_unstemmed Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
title_sort Effects of exogenous melatonin supplementation on health outcomes: An umbrella review of meta-analyses based on randomized controlled trials.
dc.creator.none.fl_str_mv Lim S
Park S
Koyanagi A
Yang JW
Jacob L
Yon DK
Lee SW
Kim MS
Il Shin J
Smith L
author Lim S
author_facet Lim S
Park S
Koyanagi A
Yang JW
Jacob L
Yon DK
Lee SW
Kim MS
Il Shin J
Smith L
author_role author
author2 Park S
Koyanagi A
Yang JW
Jacob L
Yon DK
Lee SW
Kim MS
Il Shin J
Smith L
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Alprazolam (PubChem CID:2118)
Clinical outcome
Clozapine (PubChem CID:135398737)
Inositol (PubChem CID:892)
Melatonin
Melatonin (PubChem CID:896)
Midazolam (PubChem CID:4192)
Olanzapine (PubChem CID:135398745)
Oxazepam (PubChem CID:4616)
Quetiapine (PubChem CID:5002)
Randomized controlled trial
Risperidone (PubChem CID:5073)
Umbrella review
topic Alprazolam (PubChem CID:2118)
Clinical outcome
Clozapine (PubChem CID:135398737)
Inositol (PubChem CID:892)
Melatonin
Melatonin (PubChem CID:896)
Midazolam (PubChem CID:4192)
Olanzapine (PubChem CID:135398745)
Oxazepam (PubChem CID:4616)
Quetiapine (PubChem CID:5002)
Randomized controlled trial
Risperidone (PubChem CID:5073)
Umbrella review
description Various melatonin supplementations have been developed to improve health outcomes in various clinical conditions. Thus, we sought to evaluate and summarize the effect of melatonin treatments in clinical settings for health outcomes. We searched PubMed/Medline, Embase, and Cochrane Library from inception to 4 February 2021. We included meta-analyses of randomized controlled trials investigating the melatonin intervention for any health outcome. Based on the different effect sizes of each meta-analysis, we calculated random models' standardized mean differences or risk ratios. We observed robust evidence supported by statistical significance with non-considerable heterogeneity between studies for sleep-related problems, cancer, surgical patients, and pregnant women. Patients with sleep disorder, sleep onset latency (SMD 0.33, 95% CI: 0.10 - 0.56, P < 0.01) were significantly improved whereas no clear evidence was shown with sleep efficiency (1.10, 95% CI: -0.26 to 2.45). The first analgesic requirement time (SMD 5.81, 95% CI: 2.57-9.05, P < 0.001) of surgical patients was distinctly improved. Female patients under artificial reproductive technologies had significant increase in the top-quality embryos (SMD 0.53, 95% CI: 0.27 - 0.79, P < 0.001), but no statistically clear evidence was found in the live birth rate (SMD 1.20, 95% CI: 0.83 - 1.72). Survival at one year (RR 1.90, 95% CI: 1.28 - 2.83, P < 0.005) significantly increased with cancer patients. Research on melatonin interventions to treat clinical symptoms and sleep problems among diverse health conditions was identified and provided considerable evidence. Future well-designed randomized clinical trials of high quality and subgroup quantitative analyses are essential.
publishDate 2022
dc.date.none.fl_str_mv 2022
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20521
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=20521
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
publisher.none.fl_str_mv ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
dc.source.none.fl_str_mv PHARMACOLOGICAL RESEARCH
ISSN: 10436618
ISSNe: 10961186
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869419438922530816
score 15,811543

Similares en LA Referencia